The Potential Use of Mesenchymal Stem Cells and Their Derived Exosomes as Immunomodulatory Agents for COVID-19 Patients
A novel severe acute respiratory syndrome coronavirus (SARS-CoV-2) causing lethal acute respiratory disease emerged in December 2019. The World Health Organization named this disease “COVID-19” and declared it a pandemic on March 11, 2020. Many studies have shown that mesenchymal stem cells (MSCs) a...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-01-01
|
| Series: | Stem Cells International |
| Online Access: | http://dx.doi.org/10.1155/2020/8835986 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832556795901509632 |
|---|---|
| author | Faisal A. Alzahrani Islam M. Saadeldin Abrar Ahmad Dipak Kumar Esam I. Azhar Arif Jamal Siddiqui Bassem Kurdi Abdulrahim Sajini Abdulmajeed F. Alrefaei Sadaf Jahan |
| author_facet | Faisal A. Alzahrani Islam M. Saadeldin Abrar Ahmad Dipak Kumar Esam I. Azhar Arif Jamal Siddiqui Bassem Kurdi Abdulrahim Sajini Abdulmajeed F. Alrefaei Sadaf Jahan |
| author_sort | Faisal A. Alzahrani |
| collection | DOAJ |
| description | A novel severe acute respiratory syndrome coronavirus (SARS-CoV-2) causing lethal acute respiratory disease emerged in December 2019. The World Health Organization named this disease “COVID-19” and declared it a pandemic on March 11, 2020. Many studies have shown that mesenchymal stem cells (MSCs) and their exosomes (MSCs-Exo), which are isolated from allogenic bone marrow stem cells, significantly lower the risk of alveolar inflammation and other pathological conditions associated with distinct lung injuries. For example, in acute respiratory distress syndrome (ARDS) and pneumonia patients, MSCs-Exo and MSCs provide similar healing properties and some clinical trials have used cell-based inhalation therapy which show great promise. MSCs and MSCs-Exo have shown potential in clinical trials as a therapeutic tool for severely affected COVID-19 patients when compared to other cell-based therapies, which may face challenges like the cells’ sticking to the respiratory tract epithelia during administration. However, the use of MSCs or MSCs-Exo for treating COVID-19 should strictly adhere to the appropriate manufacturing practices, quality control measurements, preclinical safety and efficacy data, and the proper ethical regulations. This review highlights the available clinical trials that support the therapeutic potential of MSCs or MSCs-Exo in severely affected COVID-19 patients. |
| format | Article |
| id | doaj-art-131c4720f39b4e73bff1bcfbb1378480 |
| institution | Kabale University |
| issn | 1687-966X 1687-9678 |
| language | English |
| publishDate | 2020-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Stem Cells International |
| spelling | doaj-art-131c4720f39b4e73bff1bcfbb13784802025-02-03T05:44:15ZengWileyStem Cells International1687-966X1687-96782020-01-01202010.1155/2020/88359868835986The Potential Use of Mesenchymal Stem Cells and Their Derived Exosomes as Immunomodulatory Agents for COVID-19 PatientsFaisal A. Alzahrani0Islam M. Saadeldin1Abrar Ahmad2Dipak Kumar3Esam I. Azhar4Arif Jamal Siddiqui5Bassem Kurdi6Abdulrahim Sajini7Abdulmajeed F. Alrefaei8Sadaf Jahan9Department of Biochemistry, Faculty of Science, Embryonic Stem Cell Unit, King Fahad Center for Medical Research, King Abdulaziz University, Jeddah, Saudi ArabiaDepartment of Physiology, Faculty of Veterinary Medicine, Zagazig University, Zagazig 44519, EgyptDepartment of Biochemistry, Faculty of Science, Embryonic Stem Cell Unit, King Fahad Center for Medical Research, King Abdulaziz University, Jeddah, Saudi ArabiaZoology Department, KKM College, Munger University, Jamui, IndiaDepartment of Medical Laboratories, College of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi ArabiaDepartment of Biology, College of Science, University of Hail, Hail, Saudi ArabiaDepartment of Pediatrics, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi ArabiaDepartment of Biomedical Engineering, Khalifa University of Science and Technology, Abu Dhabi, UAEJamoum University College, Department of Biology, University of Umm Al-Qura, Saudi ArabiaCollege of Applied Medical Science, Majmaah University, Al Majmaah, Saudi ArabiaA novel severe acute respiratory syndrome coronavirus (SARS-CoV-2) causing lethal acute respiratory disease emerged in December 2019. The World Health Organization named this disease “COVID-19” and declared it a pandemic on March 11, 2020. Many studies have shown that mesenchymal stem cells (MSCs) and their exosomes (MSCs-Exo), which are isolated from allogenic bone marrow stem cells, significantly lower the risk of alveolar inflammation and other pathological conditions associated with distinct lung injuries. For example, in acute respiratory distress syndrome (ARDS) and pneumonia patients, MSCs-Exo and MSCs provide similar healing properties and some clinical trials have used cell-based inhalation therapy which show great promise. MSCs and MSCs-Exo have shown potential in clinical trials as a therapeutic tool for severely affected COVID-19 patients when compared to other cell-based therapies, which may face challenges like the cells’ sticking to the respiratory tract epithelia during administration. However, the use of MSCs or MSCs-Exo for treating COVID-19 should strictly adhere to the appropriate manufacturing practices, quality control measurements, preclinical safety and efficacy data, and the proper ethical regulations. This review highlights the available clinical trials that support the therapeutic potential of MSCs or MSCs-Exo in severely affected COVID-19 patients.http://dx.doi.org/10.1155/2020/8835986 |
| spellingShingle | Faisal A. Alzahrani Islam M. Saadeldin Abrar Ahmad Dipak Kumar Esam I. Azhar Arif Jamal Siddiqui Bassem Kurdi Abdulrahim Sajini Abdulmajeed F. Alrefaei Sadaf Jahan The Potential Use of Mesenchymal Stem Cells and Their Derived Exosomes as Immunomodulatory Agents for COVID-19 Patients Stem Cells International |
| title | The Potential Use of Mesenchymal Stem Cells and Their Derived Exosomes as Immunomodulatory Agents for COVID-19 Patients |
| title_full | The Potential Use of Mesenchymal Stem Cells and Their Derived Exosomes as Immunomodulatory Agents for COVID-19 Patients |
| title_fullStr | The Potential Use of Mesenchymal Stem Cells and Their Derived Exosomes as Immunomodulatory Agents for COVID-19 Patients |
| title_full_unstemmed | The Potential Use of Mesenchymal Stem Cells and Their Derived Exosomes as Immunomodulatory Agents for COVID-19 Patients |
| title_short | The Potential Use of Mesenchymal Stem Cells and Their Derived Exosomes as Immunomodulatory Agents for COVID-19 Patients |
| title_sort | potential use of mesenchymal stem cells and their derived exosomes as immunomodulatory agents for covid 19 patients |
| url | http://dx.doi.org/10.1155/2020/8835986 |
| work_keys_str_mv | AT faisalaalzahrani thepotentialuseofmesenchymalstemcellsandtheirderivedexosomesasimmunomodulatoryagentsforcovid19patients AT islammsaadeldin thepotentialuseofmesenchymalstemcellsandtheirderivedexosomesasimmunomodulatoryagentsforcovid19patients AT abrarahmad thepotentialuseofmesenchymalstemcellsandtheirderivedexosomesasimmunomodulatoryagentsforcovid19patients AT dipakkumar thepotentialuseofmesenchymalstemcellsandtheirderivedexosomesasimmunomodulatoryagentsforcovid19patients AT esamiazhar thepotentialuseofmesenchymalstemcellsandtheirderivedexosomesasimmunomodulatoryagentsforcovid19patients AT arifjamalsiddiqui thepotentialuseofmesenchymalstemcellsandtheirderivedexosomesasimmunomodulatoryagentsforcovid19patients AT bassemkurdi thepotentialuseofmesenchymalstemcellsandtheirderivedexosomesasimmunomodulatoryagentsforcovid19patients AT abdulrahimsajini thepotentialuseofmesenchymalstemcellsandtheirderivedexosomesasimmunomodulatoryagentsforcovid19patients AT abdulmajeedfalrefaei thepotentialuseofmesenchymalstemcellsandtheirderivedexosomesasimmunomodulatoryagentsforcovid19patients AT sadafjahan thepotentialuseofmesenchymalstemcellsandtheirderivedexosomesasimmunomodulatoryagentsforcovid19patients AT faisalaalzahrani potentialuseofmesenchymalstemcellsandtheirderivedexosomesasimmunomodulatoryagentsforcovid19patients AT islammsaadeldin potentialuseofmesenchymalstemcellsandtheirderivedexosomesasimmunomodulatoryagentsforcovid19patients AT abrarahmad potentialuseofmesenchymalstemcellsandtheirderivedexosomesasimmunomodulatoryagentsforcovid19patients AT dipakkumar potentialuseofmesenchymalstemcellsandtheirderivedexosomesasimmunomodulatoryagentsforcovid19patients AT esamiazhar potentialuseofmesenchymalstemcellsandtheirderivedexosomesasimmunomodulatoryagentsforcovid19patients AT arifjamalsiddiqui potentialuseofmesenchymalstemcellsandtheirderivedexosomesasimmunomodulatoryagentsforcovid19patients AT bassemkurdi potentialuseofmesenchymalstemcellsandtheirderivedexosomesasimmunomodulatoryagentsforcovid19patients AT abdulrahimsajini potentialuseofmesenchymalstemcellsandtheirderivedexosomesasimmunomodulatoryagentsforcovid19patients AT abdulmajeedfalrefaei potentialuseofmesenchymalstemcellsandtheirderivedexosomesasimmunomodulatoryagentsforcovid19patients AT sadafjahan potentialuseofmesenchymalstemcellsandtheirderivedexosomesasimmunomodulatoryagentsforcovid19patients |